skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Small molecule inhibitors of the SARS-CoV Nsp15 endoribonuclease

Original Research

(2471) Views  (796) Full article downloads

Authors: J Ortiz-Alcantara, K Bhardwaj, S Palaninathan, et al.

Published Date September 2010 Volume 2010:2 Pages 125 - 133
DOI: http://dx.doi.org/10.2147/VAAT.S12733

J Ortiz-Alcantara1, K Bhardwaj2, S Palaninathan1, M Frieman3, RS Baric3, CC Kao2

1Department of Biochemistry and Biophysics, Texas A&M University College Station, TX, USA; 2Department of Molecular Cellular Biochemistry, Indiana University, Bloomington IN, USA; 3Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Abstract: The severe acute respiratory syndrome (SARS) virus encodes several unusual RNA processing enzymes, including Nsp15, an endoribonuclease that preferentially cleaves 3’ of uridylates through a ribonuclease A (RNase A)-like mechanism. Crystal structures of Nsp15 confirmed that the Nsp15 active site is structurally similar to that of RNase A. These similarities and our molecular docking analysis lead us to hypothesize that previously characterized RNase A inhibitors will also inhibit the SARS-CoV Nsp15. Benzopurpurin B, C-467929, C-473872, N-306711, N-65828, N-103019 and congo red were tested for effects on Nsp15 endoribonuclease activity. A fluorescence assay revealed that the IC50 values for inhibiting endoribonuclease activity were between 0.2 µM and 40 µM. These compounds were demonstrated to bind SARS-CoV Nsp15 by a differential scanning fluorimetry assay. Benzopurpurin B also inhibited the endoribonuclease activities of the Nsp15 orthologs from two other coronaviruses: mouse hepatitis virus (MHV) and infectious bronchitis virus (IBV). Benzopurpurin B, C-473872, and congo red reduced infectivity of MHV in L2 cells by 8- to 26- fold. The more effective drugs caused a decrease in MHV RNA accumulation. All three compounds reduced the infectivity of the SARS-CoV in Vero cells.

Keywords: SARS, endoribonuclease, small molecule inhibitors




 

Other articles by Dr C Kao



Readers of this article also read:

A review and critique of assessment instruments for patients with persistent pain
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease
Conformations of the monomeric hepatitis C virus RNA-dependent RNA polymerase
Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children
An update on small molecule inhibitors of the HCV NS5B polymerase: effects on RNA synthesis in vitro and in cultured cells, and potential resistance in viral quasispecies
The role of herpesviruses in ocular infections
p38 and STAT3 activation by vGPCR in KSHV-infected cells
Enucleation following treatment with intravenous pentamidine for Acanthamoeba sclerokeratitis
Mapping protein–RNA interactions
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio